References
1. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br. J. Haematol. 2010;149:578‑86.
2. Altman A. Acute tumor lysis syndrome. Semin. Oncol. 2001;28:3‑8.
3. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk. Lymphoma 2003;44:77‑83.
4. Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv. Chronic Kidney Dis. 2014;21:18‑26.
5. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am. J. Med. 1993;94:133‑9.
6. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736‑43.
7. Seidemann K, Meyer U, Jansen P, Yakisan E, Rieske K, Führer M, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with Non-Hodgkin’s Lymphoma and B-ALL. Klin. Pädiatr. 1998;210:279‑84.
8. Stephanos K, Picard L. Pediatric Oncologic Emergencies. Emerg. Med. Clin. North Am. 2018;36:527‑35.
9. Montesinos P, Lorenzo I, Martin G, Sanz J, Perez-Sirvent ML, Martinez D, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008;93:67‑74.
10. Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015;26:2155‑61.
11. Yu X, Liu L, Nie X, Li J, Zhang J, Zhao L, et al. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. J. Clin. Pharm. Ther. 2017;42:18‑26.
12. Alakel N, Middeke JM, Schetelig J, Bornhäuser M. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OncoTargets Ther. 2017;10:597‑605.
13. McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br. J. Haematol. 2010;149:638‑52.
14. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. N. Engl. J. Med. 2002;346:235‑42.
15. Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2016;375:1044‑53.
16. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin. Oncol. 2002;29:105‑12.
17. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. N. Engl. J. Med. 1993;329:987‑94.
18. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 2004;127:3‑11.
19. Chamuleau MED. Chamuleau MED, Stenner F, Chitu D, et al. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma: first results of a multi-center randomized HOVON/SAKK trial. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. Abstract LB2370. 2022.
20. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N. Engl. J. Med. 2011;364:1844‑54.
21. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J. Clin. Oncol. 37:11.
22. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am. J. Med. 1993;94:133‑9.
23. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J. Clin. Oncol. 2020;38:2519‑29.
24. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d’Oncologie PédiatriqueLMB89 protocol. Ann. Oncol. 2002;13:789‑95.
25. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, et al. Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. J. Clin. Oncol. 2003;21:4402‑6.
26. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (ElitekTM), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34‑8.
27. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an International Compassionate Use Study. Cancer 2003;98:1048‑54.
28. Ribrag DV. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. 2016;387:10.
29. Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst. Rev. [Internet] 2017 [cité 2023 avr 21];2017. Available from: http://doi.wiley.com/10.1002/14651858.CD006945.pub4
30. Hyman CB, Sturgeon P. Prednison therapy of acute lymphatic leukemia in children. Cancer 1956;9:965‑70.
31. Malpica L, Mufuka B, Galeotti J, Tan X, Grover N, Clark SM, et al. A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas. Leuk. Lymphoma 2020;61:1508‑11.
32. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103‑10.
33. Lakshmaiah KC, Asati V, Babu K G, D L, Jacob LA, M C SB, et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur. J. Haematol. 2018;100:644‑8.
34. Cui Y, Li X, Sun Z, Leng C, Young K, Wu X, et al. Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leuk. Lymphoma 2015;56:2613‑8.
35. Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4:e46‑55.
36. Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev. Clin. Immunol. 2019;15:383‑9.
37. Amitai I, Gafter‐Gvili A, Shargian‐Alon L, Raanani P, Gurion R. Obinutuzumab‐related adverse events: A systematic review and meta‐analysis. Hematol. Oncol. 2021;39:215‑21.
38. Courville J, Nastoupil L, Kaila N, Kelton J, Zhang J, Alcasid A, et al. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs 2021;35:459‑68.
39. Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int. J. Clin. Pharm. 2017;39:380‑5.
40. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022;387:2220‑31.
41. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2018;378:1107‑20.